Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Intercommunal Creteil
About this trial
To evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without COPD compared to non-smokers patients
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18
Patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer
Acceptance to participate in the protocol
Affiliated to a social security plan
Disqualifiers
Chronic autoimmune disease
Patient under guardianship or curators
Neo-adjuvant chemotherapy
History of thoracic radiotherapy
Trial design
Design model
Single group
Treatments tested in this trial
Thoracic resection surgery
Other interventionPatients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
Treatment groups
186 Participants
are divided into 1 treatment groupGroup A: Thoracic resection surgeryOther 1 intervention
Trial outcomes
Primary outcomes
1
Number of alveolar organoids
Comparison of the number of alveolar organoids formed 21 days after culture of fibroblasts with alveolar type II cells between smokers with and without COPD and non-smoking patients
Time frame
through study completion, an average of 3 yearsSecondary outcomes
1
Fibroblast proliferation capacity
Evaluated by their doubling time, number of cells collected compared to the number of cells seeded
Time frame
through study completion, an average of 3 years2
Differentiation into myofibroblasts
By immunofluorescence marking: number of alpha-smooth muscle actin (alpha-SMA) + cells compared to total cells
Time frame
through study completion, an average of 3 years3
Fibroblast migration capacity
Evaluated in Boyden chamber
Time frame
through study completion, an average of 3 years4
Modulated signaling pathways in isolated fibroblasts between groups
Evaluated by Ribonucleic acid (RNA) sequencing of fibroblasts
Time frame
through study completion, an average of 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Centre Hospitalier Intercommunal Creteil
Lead sponsor
Henri Mondor University Hospital
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
Source ClinicalTrials.gov